« Back to report listing





Number of Pages:101

standard report icon

Global Colorectal Cancer

Market and Pipeline Analysis 2010-2013


The Market and Pipeline Analysis report focused on Global Colorectal Cancer provides a look at the evolved therapies and drugs currently being used in treatments, as well as those in development. As one of the most common forms of cancer, the market for this area is rapidly growing and changing. Global market potential is an important component to this report, as variances by countries are highlighted.


Colorectal cancer is the third most common cancer in women and fourth most common cancer in men. Colorectal cancer is more prevalent in highly developed countries and is responsible for the death of approximately 660,000 people worldwide. Physical inactivity, obesity, diet low in fruits and vegetables and high in red meat and smoking are considered to be the key risk factors for colorectal cancer. It usually affects people beyond the age of 50. This cancer of the colon and the rectum is often detected when the cancer has reached late stage or has metastasized to nearby organs. Hence, countries that have high colorectal cancer incidences are implementing screening procedures and programs that allow colorectal cancer to be detected before it reaches late stage. These precautionary measures have led to early detection of the cancer and subsequent treatment, allowing for an increase in survival rates.

Surgery, radiation therapy, chemotherapy and use of biologics are the main weapons in the colorectal treatment armamentarium. Surgical treatment of colorectal cancer involves surgical removal of the tumor to prevent its growth and spread. Common surgical procedures are polypectomy, colectomy, colostomy and resection. Radiation therapy involves the use of radiation, internal or external, to kill any remaining cancer cells after surgery. While chemotherapy involves using chemicals to kill the cancer cells, targeted therapy uses synthetically developed monoclonal antibodies or small molecules, which target certain specific characteristics of cancer cells, leading to their destruction without affecting the normal cells.

The Colorectal Cancer Market Analysis

The colorectal cancer market has evolved from the use of 5-Fluoropyrimidine/Leucovorin to cytotoxic agents, Oxaliplatin and Irinotecan to the newly introduced targeted therapy of biologics. A combination of chemotherapy with targeted therapy is the most common form of treatment regimen used in developed countries.

The global colorectal cancer market for is estimated to be valued at $7.35 billion for the base year 2009. The market is expected to grow at a cumulative annual growth rate of 7.2 percent over the forecast period and reach $10.41 billion by end of the forecast period, 2014. Increased use of biologics such as Avastin, Erbitux and Vectibix, a strong biologics pipeline, and entry of generic Oxaliplatin and Irinotecan are the key factors impacting the growth of the colorectal cancer market.


  • Chapter 1: Overview of Colorectal Cancer
    • Epidemiology of Colorectal Cancer
  • Chapter 2: Introduction to Colorectal Cancer Treatment
    • Staging of Colorectal Cancer
    • Treatment of Colorectal Cancer
    • Colorectal Cancer Treatment Algorithm
    • Colorectal Cancer Treatment Timeline / Prior to biologics
  • Chapter 3: Colorectal Cancer Therapeutic Area Overview
    • Chemotherapy
    • Targeted therapy
  • Chapter 4: Colorectal Cancer Market Analysis
    • The Global Colorectal Cancer Market
    • Global Colorectal Market by Segment
    • Impact of Generics
  • Chapter 5: Competitive Analysis
    • Product Analysis
    • Company Analysis
  • Chapter 6: Pipeline and Clinical Data Analysis
    • Colorectal Cancer Pipeline Analysis
    • Clinical Data and its Impact
    • Results of Select Clinical Trials
    • Clinical Trials List of Key Targeted Drugs
    • Late Stage Analysis of Key of Colorectal Cancer Pipeline Drugs
  • Chapter 7: Colorectal Cancer Market, Analysis by Geography
    • Analysis by Region
  • Chapter 8: Summary


  • Bristol-Myers Squibb
  • Imclone
  • Eli Lilly
  • Sanofi-Aventis
  • Amgen
  • AstraZeneca
  • Pfizer
  • Barr
  • Teva
  • APP
  • Taiho
  • Roche/Genentech
  • Biodel
  • Merck KgaA
  • Mylan
  • Hospira
  • Sandoz
  • Ranbaxy
  • Actavis
  • Bayer
  • Merck Serono
  • GlaxoSmithKline
  • Light Sciences Oncology
  • Yakult Honsha
  • Daiichi Sankyo
  • OSI
  • Onyx
  • Poniard
  • Chugai


  • Avastin (bevacizumab)
  • Erbitux (cetuximab)
  • Vectibix (panitumumab)
  • Eloxatin
  • Elplat
  • Foloxatine
  • Transplatin (Oxaliplatin)
  • Brivanib
  • Aflibercept
  • Recentin (cediranib)
  • Axitinib
  • IMC-11F8 (necitumumab)
  • Adrucil (5-FU, 5-Fluorouracil)
  • Wellcovorin (Leucovorin, LV)
  • Xeloda (Capecitabine)
  • Camptosar (Irinotecan)
  • TS-1 (S-1)
  • Uftoral (UFT, Uracil, Tegafur)
  • Cyclophosphamide
  • Ifosfamide
  • Melphalan
  • Thiopeta
  • Busulphan
  • Dacarbazine
  • Capezitabine
  • Gemzitabine
  • Idarubincin
  • Mitoxantrone
  • Epirubicin
  • Bleomycin
  • Tapotecin
  • Paclitaxel
  • Docetaxel
  • Cisplatin
  • Carboplatin
  • Tarceva
  • Litx
  • Picoplatin
  • Nexavar
  • DI1756
  • Adecatumumab
  • Topoisomerase I Inh/TP3001
  • Hedgehog Pathway Inh/GDC0449 (RG3616)
  • COIN
  • PRIME 203
  • Sutent: SUN 1122
  • NSABP C-08
  • Votrient